Back to Stock Dashboard
Sector:
Consumer Cyclical
Add to portfolio
PHSE
Pharmhouse Corp
Pharmhouse Corp (PHSE) is rated C (2.3/5) on Deltasharpe Prism, scored against Consumer Cyclical sector peers. Its strongest pillar is Growth (B+); its weakest is Revisions (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.3
/ 5.0
C
Value
C
Factor Score
2.3
/ 5.0
Growth
B+
Factor Score
3.6
/ 5.0
Profitability
D+
Factor Score
1.7
/ 5.0
Momentum
C-
Factor Score
2.0
/ 5.0
Revisions
D+
Factor Score
1.7
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
0.0
Rev Growth YoY
190.8%
Gross Margin
13.5%
Price Return 3M
-62.5%
Price Return 12M
-52.5%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
6.6K
ROE
-56.7%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C (2.3) | B+ (3.6) | D+ (1.7) | C- (2.0) | D+ (1.7) | C (2.3) |
| 2026-08-04 | C (2.3) | B+ (3.6) | D+ (1.7) | C- (2.1) | D+ (1.8) | C (2.3) |
| 2026-08-03 | C (2.3) | C+ (2.7) | C- (2.0) | C (2.3) | D+ (1.8) | C (2.2) |
| 2026-08-02 | C (2.3) | C+ (2.7) | C- (2.0) | C (2.2) | D+ (1.8) | C (2.2) |